Press releases
These press releases are intended for journalists and analysts/investors.
-
Medicines Research Unit to Close
GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney
-
GSK Open Innovation brings opportunities to Australian & NZ innovators
Australian and New Zealand health innovators encouraged to apply for partnership with GSK to turn their ideas into reality
-
GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)
Panadol is approved by the TGA for the effective relief of backache
-
New medicine for lupus now available in Australia
GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients
-
Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium)
-
Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration
-
GSK Recognises Top Poppy Growers
Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner held in Launceston last week
-
$80,000 to local communities to boost immunisation
GSK’s 2014 Immunisation Grants for local communities were launched today at the Public Health Association of Australia’s 14th annual
-
GSK Response to CHOICE Media Release
GSK has previously provided detailed product information and clinical studies to CHOICE and would like to respond to some of the allegation
-
GSK Australia Reports 2013 results to ASIC
GSK Australia reported to the Australian Securities and Investment Commission (ASIC) for 2013, sales of $1,414m
-
Skin Science Facility to Close in Rowville, Victoria
GSK announced today the immediate closure of the Stiefel, skin science facility in Rowville, Victoria
-
2013 Corporate Responsibility Report Published
GSK Australia and New Zealand today published the second annual corporate responsibility report, outlining key achievements in health
-
Positive poppy trial results encourage on-going investigation
Positive results from GSK’s 2013-14 poppy growing trials across Victoria will provide a sound foundation for more targeted trials
-
GSK discloses 2013 payments to Australian healthcare professionals
As part of our ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid
-
GSK encourages research excellence as award nominations open
GSK has opened nominations for what is regarded as one of the most prestigious research awards available to the Australian science
-
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and COPD
GSK Australia and Theravance, Inc. (NASDAQ: THRX) have proudly announced today that the Therapeutic Goods Administration (TGA)
-
GSK innovation starts to relieve the urge to smoke in 50 seconds
GSK Australia launched today a new innovative product Nicabate Oral Strips that starts to* relieve the urge to smoke in just 50 seconds
-
Illuminate your smile with the new Macleans® High Definition™ White range
We all know how important it is to present our best possible self, unleashing the unmistakable feeling of illumination
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GlaxoSmithKline plc (LSE:GSK) today announced its decision to stop the MAGRITi trial
-
GSK brings New Zealand to the forefront in new Panadol® brand campaign
A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally
